These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1385136)

  • 1. New ultrasensitive assay development by using monoclonal antibodies for detecting prostate-specific antigen.
    Di Silverio F; D'Eramo G; Flammia GP; Caponera M; Macrí D; Loreto A; Sciarra A
    Eur Urol; 1992; 21 Suppl 1():79-82. PubMed ID: 1385136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
    Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
    Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
    Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
    Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Schambeck C; Fateh-Moghadam A
    Tumour Biol; 1997; 18(2):80-7. PubMed ID: 9222305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
    Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
    Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
    Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
    J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
    Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
    Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
    Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
    Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
    JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.